Efficacy and safety of dabrafenib–trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF‐V600 mutation: A systematic review and network meta‐analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of dabrafenib–trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF‐V600 mutation: A systematic review and network meta‐analysis

Published:2019-11-14 Issue:2 Volume:33 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Garzón‐Orjuela Nathaly¹^ORCID,Prieto‐Pinto Laura¹,Lasalvia Pieralessandro¹,Herrera Daniel²,Castrillón Johanna³,González‐Bravo Diana¹,Castañeda‐Cardona Camilo¹,Rosselli Diego¹⁴

Affiliation:

1. Department of Evidence‐Based Medicine NeuroEconomix Bogotá Colombia

2. Department of Medical ‐ Oncology Unit Novartis Bogotá Colombia

3. Department of Market Access Novartis Bogota Colombia

4. Clinical Epidemiology and Biostatistics Department Pontificia Universidad Javeriana, Medical School Bogotá Colombia

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.13145

Reference44 articles.

1. Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma

2. BRAF inhibitors in metastatic non-small cell lung cancer

3. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

4. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

5. Actualidades en el tratamiento del melanoma en etapas avanzadas;Ayala‐Cortés A.;Gaceta Médica de México,2014

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive insights on genetic alterations and immunotherapy prognosis in Chinese melanoma patients;Scientific Reports;2024-07-18

2. Dabrafenib plus trametinib in unselected advanced BRAF V600–mut melanoma: a non-interventional, multicenter, prospective trial;Melanoma Research;2023-12-13

3. Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report;Case Reports in Oncology;2023-11-24

4. Dabrafenib plus trametinib versus nivolumab for advanced melanoma;Medwave;2023-02-27

5. Safety and efficacy of nivolumab compared with other regimens in patients with melanoma: A network meta-analysis;Medicine;2022-09-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3